Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financial Results and Clinical Program Updates Mar 16, 2023 07:30AM
Fusion Pharmaceuticals (FUSN) Announces 17.6M Share Offering at $3.40/sh, Acquires Phase 2 Program for 225Ac-PSMA I&T Feb 13, 2023 04:06PM
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer Feb 13, 2023 04:05PM